Multidrug evolutionary strategies to reverse antibiotic resistance

被引:572
作者
Baym, Michael [1 ]
Stone, Laura K. [1 ]
Kishony, Roy [1 ,2 ,3 ]
机构
[1] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA
[2] Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel
[3] Technion Israel Inst Technol, Dept Comp Sci, IL-32000 Haifa, Israel
基金
美国国家卫生研究院; 欧洲研究理事会;
关键词
NEGATIVE CROSS-RESISTANCE; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; COLLATERAL SENSITIVITY; RIFAMPICIN-RESISTANCE; MOLECULAR-MECHANISMS; BACTERIAL EVOLUTION; DRUG-INTERACTIONS; HUMAN HEALTH; EFFLUX PUMP;
D O I
10.1126/science.aad3292
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];
摘要
Antibiotic treatment has two conflicting effects: the desired, immediate effect of inhibiting bacterial growth and the undesired, long-term effect of promoting the evolution of resistance. Although these contrasting outcomes seem inextricably linked, recent work has revealed several ways by which antibiotics can be combined to inhibit bacterial growth while, counterintuitively, selecting against resistant mutants. Decoupling treatment efficacy from the risk of resistance can be achieved by exploiting specific interactions between drugs, and the ways in which resistance mutations to a given drug can modulate these interactions or increase the sensitivity of the bacteria to other compounds. Although their practical application requires much further development and validation, and relies on advances in genomic diagnostics, these discoveries suggest novel paradigms that may restrict or even reverse the evolution of resistance.
引用
收藏
页数:5
相关论文
共 124 条
[1]
Abraham EP, 1941, LANCET, V2, P177
[2]
Molecular mechanisms of antibacterial multidrug resistance [J].
Alekshun, Michael N. ;
Levy, Stuart B. .
CELL, 2007, 128 (06) :1037-1050
[3]
7-HYDROXYTROPOLONE - AN INHIBITOR OF AMINOGLYCOSIDE-2''-O-ADENYLYLTRANSFERASE [J].
ALLEN, NE ;
ALBORN, WE ;
HOBBS, JN ;
KIRST, HA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 22 (05) :824-831
[4]
Targeting virulence: can we make evolution-proof drugs? [J].
Allen, Richard C. ;
Popat, Roman ;
Diggle, Stephen P. ;
Brown, Sam P. .
NATURE REVIEWS MICROBIOLOGY, 2014, 12 (04) :300-308
[5]
Metabolite-enabled eradication of bacterial persisters by aminoglycosides [J].
Allison, Kyle R. ;
Brynildsen, Mark P. ;
Collins, James J. .
NATURE, 2011, 473 (7346) :216-+
[6]
Antibiotic resistance and its cost: is it possible to reverse resistance? [J].
Andersson, Dan I. ;
Hughes, Diarmaid .
NATURE REVIEWS MICROBIOLOGY, 2010, 8 (04) :260-271
[7]
[Anonymous], 2014, Recommendations to the President, P1, DOI DOI 10.1111/J.0033-0124.1964.033_G.X
[8]
[Anonymous], 2013, Threat Report, P50
[9]
Tracing of false negative results in phenotypic methods for identification of carbapenemase by Real-time PCR [J].
Azimi, Leila ;
Talebi, Malihe ;
Owlia, Parviz ;
Pourshafie, Mohammad-Reza ;
Najafi, Mohamad ;
Lari, Elnaz Rastegar ;
Lari, Abdolaziz Rastegar .
GENE, 2016, 576 (01) :166-170
[10]
Conclusions:: the future of antimicrobial therapy -: Augmentin® and beyond [J].
Ball, Peter .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 30 :S139-S141